Implicit Bioscience identifies high-value clinical stage assets, acquires development and commercialization rights, conducts further development through important value-adding milestones, then returns value to shareholders by partnering or licensing those assets. Our competitive advantage lies in our ability to unlock value from de-risked assets, using non-dilutive funding to stretch investor capital. Implicit enters its next phase of growth with two clinical stage drugs which modulate the host immune response to disease.
- IC14 is a recombinant chimeric monoclonal antibody which recognizes and blocks the function of human CD14, a top-level master receptor controlling innate immune responses and downstream inflammation.
- The dipeptide oglufanide disodium (ODS) is being investigated in a range of indications of concern to global and personal health.